High Net Worth Advisory Group LLC Sells 2,332 Shares of Novo Nordisk A/S (NYSE:NVO)

High Net Worth Advisory Group LLC lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 49.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,384 shares of the company’s stock after selling 2,332 shares during the period. High Net Worth Advisory Group LLC’s holdings in Novo Nordisk A/S were worth $205,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in NVO. International Assets Investment Management LLC lifted its stake in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. Mediolanum International Funds Ltd acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $98,765,000. Wellington Management Group LLP bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $42,017,000. Sanctuary Advisors LLC acquired a new stake in Novo Nordisk A/S in the second quarter valued at about $41,646,000. Finally, World Investment Advisors LLC grew its position in Novo Nordisk A/S by 2,655.9% in the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after acquiring an additional 270,234 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the subject of a number of research reports. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Trading Up 8.4 %

Shares of NYSE NVO opened at $87.94 on Monday. The stock has a market cap of $394.65 billion, a P/E ratio of 28.46, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The firm has a 50 day moving average price of $95.35 and a two-hundred day moving average price of $114.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.